With the ramp-up in its existing projects set to continue in subsequent quarters, coupled with further new projects on the medical and consumer, and automotive front, we expect the positive growth...

Hyphens Pharma is one of Singapore's leading specialty pharmaceutical (pharma) and consumer healthcare groups with an Asean presence.

WE turn positive on Koufu Group, upgrading our recommendation and increasing our target price as we expect the group to post higher net earnings growth of 8.8 per cent in FY2019.

Koufu's first quarter revenue increased 4.9 per cent year-on-year (yoy) to S$57.8 million and core earnings increased by 17 per cent yoy to S$7.2 million. Both were in line with our estimates.

HIGHER contributions due to new outlets opened boosted Koufu Group's first-quarter top and bottom line.

THE following companies saw new developments that may affect trading of their shares on Wednesday:

BOUTIQUE fund investor Albizia Capital has taken a 3.6 per cent stake in Koufu Group through a married share deal, the food court and coffeeshop operator announced on Tuesday night.